AnaptysBio (NASDAQ:ANAB) Shares Gap Down – What’s Next?

AnaptysBio, Inc. (NASDAQ:ANAB) shares gapped down before the market opened on Monday . The stock had previously closed at $39.65, but opened at $32.00. AnaptysBio shares last traded at $33.35, with a volume of 395,194 shares.

Analyst Ratings Changes

Several research firms recently issued reports on ANAB. Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday. HC Wainwright increased their price objective on AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. UBS Group reaffirmed a “neutral” rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. Guggenheim upped their price target on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded AnaptysBio from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.90.

AnaptysBio Price Performance

The company has a market capitalization of $927.89 million, a P/E ratio of -11.89 and a beta of 0.16. The business’s 50-day moving average price is $28.81 and its two-hundred day moving average price is $24.73.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. Research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the business. Bleakley Financial Group LLC raised its holdings in shares of AnaptysBio by 6.5% during the 3rd quarter. Bleakley Financial Group LLC now owns 39,981 shares of the biotechnology company’s stock valued at $1,224,000 after buying an additional 2,430 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in AnaptysBio by 67.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,907 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 4,006 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in AnaptysBio by 333.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock valued at $4,446,000 after acquiring an additional 111,668 shares during the period. Profund Advisors LLC bought a new stake in AnaptysBio in the 3rd quarter valued at $201,000. Finally, Bessemer Group Inc. boosted its position in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.